drugset / Trial / NCT06649331
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2026-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW2821 | Monoclonal antibody | — | Intravenous |
| Subject | Famitinib | Small molecule | — | Oral |
| Subject | SHR-A1921 | Monoclonal antibody | — | Intravenous |
| Subject | SHR-A2009 | Other / unclassified | — | Intravenous |
| Subject | SHR-A2102 | Other / unclassified | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |